Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis

医学 内科学 肝细胞癌 荟萃分析 胃肠病学 科克伦图书馆 血液学 肿瘤科
作者
Wen Wen,Yong Zhang,Hua Zhang,Yingshuang Chen
出处
期刊:Journal of Cancer Research and Clinical Oncology [Springer Nature]
卷期号:149 (3): 969-978 被引量:6
标识
DOI:10.1007/s00432-022-04057-3
摘要

Programmed death ligand 1(PD-L1)/programmed cell death-1(PD-1) inhibitors have shown promising efficacy in unresectable patients with advanced hepatocellular carcinoma (HCC), but the results are not consistent. Our goal was to evaluate the safety and efficacy of PD-L1/PD-1 inhibitors or plus anti-CTLA-4 antibody or anti-VEGF agents for the treatment of unresectable HCC.Cochrane library, Embase, and PubMed were searched till August 2021. Data on progression-free survival (PFS), objective response rate (ORR), overall survival (OS), and disease control rate (DCR) were pooled and analyzed by Stata14 software.Thirteen prospective trials with 2,386 HCC patients were included. Pooled analysis estimated an ORR of about 0.21 (95% CI = 0.18-0.25) and a DCR of 0.59 (95% CI = 0.52-0.65) for anti-PD-1/PD-L1 therapy. Summary PFS was 4.19 (95% CI = 3.31-5.18) months and summary OS was 13.23 (95% CI = 12.06-14.41) months. After using PD-L1/PD-1 inhibitors plus anti-VEGF agents, ORR was 0.26 (95% CI = 0.20-0.33), DCR was 0.75 (95% CI = 0.69-0.81) and PFS was 6.2 (95% CI = 4.61-7.78) months. PD-L1/PD-1 inhibitors plus anti-CTLA-4 antibody therapy achieved an ORR of 0.23 (95% CI = 0.14-0.33), an DCR of 0.44 (95% CI = 0.39-0.50) and a PFS of 1.88 (95% CI = 1.51-2.26).PD-L1/PD-1 inhibitors were effective and tolerable in patients with advanced HCC. Furthermore, compared with anti-PD-1/PD-L1 monotherapy, PD-L1/PD-1 inhibitors plus anti-VEGF agents resulted in more clinical improvements in ORR, DCR, and PFS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
光年关注了科研通微信公众号
1秒前
3秒前
4秒前
安静曼彤发布了新的文献求助10
4秒前
6秒前
6秒前
zhang005on发布了新的文献求助10
7秒前
7秒前
10秒前
zsyf完成签到,获得积分10
11秒前
安静曼彤完成签到,获得积分10
11秒前
大胆荔枝发布了新的文献求助10
13秒前
14秒前
天璇发布了新的文献求助10
14秒前
健忘幼晴发布了新的文献求助10
14秒前
15秒前
Ann完成签到,获得积分10
18秒前
19秒前
19秒前
小黑应助科研通管家采纳,获得10
19秒前
科研通AI2S应助科研通管家采纳,获得10
19秒前
bkagyin应助科研通管家采纳,获得10
19秒前
19秒前
19秒前
领导范儿应助科研通管家采纳,获得10
19秒前
19秒前
Lucas应助科研通管家采纳,获得10
19秒前
科目三应助健忘幼晴采纳,获得10
25秒前
52hezi完成签到,获得积分10
26秒前
26秒前
27秒前
Thorns完成签到,获得积分10
29秒前
CrsCrsCrs完成签到,获得积分10
30秒前
荣誉完成签到,获得积分10
30秒前
小杨发布了新的文献求助10
32秒前
33秒前
37秒前
神勇乐安发布了新的文献求助30
37秒前
聪慧世界发布了新的文献求助10
37秒前
39秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2000
Agaricales of New Zealand 1: Pluteaceae - Entolomataceae 1500
Very-high-order BVD Schemes Using β-variable THINC Method 1200
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 1000
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 1000
Autoregulatory progressive resistance exercise: linear versus a velocity-based flexible model 550
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3363750
求助须知:如何正确求助?哪些是违规求助? 2984951
关于积分的说明 8715734
捐赠科研通 2667092
什么是DOI,文献DOI怎么找? 1460648
科研通“疑难数据库(出版商)”最低求助积分说明 675969
邀请新用户注册赠送积分活动 667318